Author argues Novo Nordisk is undervalued based on company guidance that pills will capture over a third of the GLP-1 obesity market by 2030.
NVO — LONG The author claims investors are underweight Novo Nordisk, citing company guidance that oral GLP-1 pills will capture over a third of the obesity market by 2030 and that the pill market is bigger than initially thought. Novo is prioritizing a U.S. launch to avoid past supply issues, which the author implies supports the growth thesis. The catalyst is the 2030 pill market opportunity and U.S. launch execution.
You don’t own enough NOVO.